Andrew Grieve, CEO of Zenabis talks about their contract cultivation partnership with Tantalus and their recent stock offering

1 min read

Andrew Grieve is the CEO of Zenabis and he joined Business of Cannabis to talk about their agreement to grow Tantalus Labs genetics on contract as well as their stock offering to current shareholders – which has been the topic of conversation among those that follow publicly traded cannabis companies.

Previous Story

Sasha Asgary, Weedsense

Next Story

BofC Live podcast featuring Honourable Anne McLellan from the Canada 2020 Canadian Grown Policy Conference October 2019

0 $0.00